News
ONCT
1.040
-6.31%
-0.070
HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated
Benzinga · 06/13 15:07
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell ...
GlobeNewswire · 06/10 20:30
Oncternal Therapeutics outlines late-stage study for mantle cell lymphoma candidate
Oncternal Therapeutics (NASDAQ:ONCT) said it will begin a phase 3 trial of ZILO-301, a combination of its experimental monocolonal antibody zilovertamab with Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) in
Seekingalpha · 06/10 15:13
BRIEF-Oncternal Therapeutics Presents Plans For Registrational Phase 3 Study Evaluating Zilovertamab In Combination With Ibrutinib
reuters.com · 06/10 13:12
Oncternal Therapeutics To Present Poster On Phase 3 ZILO-301 Trial At EHA 2022 Congress Jun. 10
 Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3
Benzinga · 06/10 13:03
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase...
GlobeNewswire · 06/10 13:00
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Jefferies H...
GlobeNewswire · 06/02 13:00
Oncternal Therapeutics grants clinical science head options for 70K shares
Oncternal Therapeutics (NASDAQ:ONCT) granted options to buy 70K common shares to its new employee Ted Shih, who joined as head, Clinical Science. The award was made on June 1 under Oncternal's
Seekingalpha · 06/02 10:04
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new ...
GlobeNewswire · 06/01 21:00
44 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 06/01 16:14
Helius Medical, Tonix top healthcare gainers; while Enochian, Icosavax lead losers' pack
Gainers: Helius Medical Technologies (HSDT) +57%. Tonix Pharmaceuticals  (TNXP) +49%. NeuroOne Medical Technologies (NMTC) +16%. Oncternal Therapeutics (ONCT) +16%. Butterfly Network (BFLY) +15%. Losers: Enochian Biosciences (ENOB) -37%. Icosavax (ICVX) -1...
Seekingalpha · 06/01 14:04
40 Stocks Moving In Tuesday's Mid-Day Session
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
Benzinga · 05/31 16:04
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/31 11:23
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Performance Shipping Inc. (NASDAQ: PSHG) rose 41.7% to $ 0.94 in pre-market trading. Performance Shipping shares dipped around 64% on Friday after the company announced the pricing of an underwritten public offering of 7,620,000 units at $1.05 per ...
Benzinga · 05/31 10:52
Mid-Afternoon Market Update: Dow Gains 500 Points; Red Robin Gourmet Burgers Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 500 points on Friday.
Benzinga · 05/27 19:30
Mid-Day Market Update: Nasdaq Jumps 300 Points; Aurora Cannabis Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping around 300 points on Friday.
Benzinga · 05/27 18:24
41 Stocks Moving In Friday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Benzinga · 05/27 18:13
BRIEF-Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At Asco 2022
reuters.com · 05/26 23:44
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 05/26 22:13
Oncternal Therapeutics To Present At ASCO Jun. 4
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with
Benzinga · 05/26 21:16
More
Webull provides a variety of real-time ONCT stock news. You can receive the latest news about Oncternal Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.